author_facet Puri, A.
Gulia, A.
Puri, A.
Gulia, A.
author Puri, A.
Gulia, A.
spellingShingle Puri, A.
Gulia, A.
The Journal of Bone and Joint Surgery. British volume
The results of total humeral replacement following excision for primary bone tumour
Orthopedics and Sports Medicine
Surgery
author_sort puri, a.
spelling Puri, A. Gulia, A. 0301-620X 2044-5377 British Editorial Society of Bone & Joint Surgery Orthopedics and Sports Medicine Surgery http://dx.doi.org/10.1302/0301-620x.94b9.29697 <jats:p>Rarely, the extent of a malignant bone tumour may necessitate resection of the complete humerus to achieve adequate oncological clearance. We present our experience with reconstruction in such cases using a total humeral endoprosthesis (THER) in 20 patients (12 male and eight female) with a mean age of 22 years (6 to 59). We assessed the complications, the oncological and functional outcomes and implant survival. Surgery was performed between June 2001 and October 2009. The diagnosis included osteosarcoma in nine, Ewing’s sarcoma in eight and chondrosarcoma in three. One patient was lost to follow-up. The mean follow-up was 41 months (10 to 120) for all patients and 56 months (25 to 120) in survivors. There were five local recurrences (26.3%) and 11 patients were alive at time of last follow-up, with overall survival for all patients being 52% (95% confidence interval (CI) 23.8 to 74) at five years. The mean Musculoskeletal Tumor Society score for the survivors was 22 (73%; 16 to 23). The implant survival was 95% (95% CI 69.5 to 99.3) at five years.</jats:p><jats:p>The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.</jats:p> The results of total humeral replacement following excision for primary bone tumour The Journal of Bone and Joint Surgery. British volume
doi_str_mv 10.1302/0301-620x.94b9.29697
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTMwMi8wMzAxLTYyMHguOTRiOS4yOTY5Nw
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTMwMi8wMzAxLTYyMHguOTRiOS4yOTY5Nw
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Zi4
DE-Gla1
DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
imprint British Editorial Society of Bone & Joint Surgery, 2012
imprint_str_mv British Editorial Society of Bone & Joint Surgery, 2012
issn 0301-620X
2044-5377
issn_str_mv 0301-620X
2044-5377
language English
mega_collection British Editorial Society of Bone & Joint Surgery (CrossRef)
match_str puri2012theresultsoftotalhumeralreplacementfollowingexcisionforprimarybonetumour
publishDateSort 2012
publisher British Editorial Society of Bone & Joint Surgery
recordtype ai
record_format ai
series The Journal of Bone and Joint Surgery. British volume
source_id 49
title The results of total humeral replacement following excision for primary bone tumour
title_unstemmed The results of total humeral replacement following excision for primary bone tumour
title_full The results of total humeral replacement following excision for primary bone tumour
title_fullStr The results of total humeral replacement following excision for primary bone tumour
title_full_unstemmed The results of total humeral replacement following excision for primary bone tumour
title_short The results of total humeral replacement following excision for primary bone tumour
title_sort the results of total humeral replacement following excision for primary bone tumour
topic Orthopedics and Sports Medicine
Surgery
url http://dx.doi.org/10.1302/0301-620x.94b9.29697
publishDate 2012
physical 1277-1281
description <jats:p>Rarely, the extent of a malignant bone tumour may necessitate resection of the complete humerus to achieve adequate oncological clearance. We present our experience with reconstruction in such cases using a total humeral endoprosthesis (THER) in 20 patients (12 male and eight female) with a mean age of 22 years (6 to 59). We assessed the complications, the oncological and functional outcomes and implant survival. Surgery was performed between June 2001 and October 2009. The diagnosis included osteosarcoma in nine, Ewing’s sarcoma in eight and chondrosarcoma in three. One patient was lost to follow-up. The mean follow-up was 41 months (10 to 120) for all patients and 56 months (25 to 120) in survivors. There were five local recurrences (26.3%) and 11 patients were alive at time of last follow-up, with overall survival for all patients being 52% (95% confidence interval (CI) 23.8 to 74) at five years. The mean Musculoskeletal Tumor Society score for the survivors was 22 (73%; 16 to 23). The implant survival was 95% (95% CI 69.5 to 99.3) at five years.</jats:p><jats:p>The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.</jats:p>
container_issue 9
container_start_page 1277
container_title The Journal of Bone and Joint Surgery. British volume
container_volume 94-B
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792333392272949254
geogr_code not assigned
last_indexed 2024-03-01T14:10:54.264Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+results+of+total+humeral+replacement+following+excision+for+primary+bone+tumour&rft.date=2012-09-01&genre=article&issn=2044-5377&volume=94-B&issue=9&spage=1277&epage=1281&pages=1277-1281&jtitle=The+Journal+of+Bone+and+Joint+Surgery.+British+volume&atitle=The+results+of+total+humeral+replacement+following+excision+for+primary+bone+tumour&aulast=Gulia&aufirst=A.&rft_id=info%3Adoi%2F10.1302%2F0301-620x.94b9.29697&rft.language%5B0%5D=eng
SOLR
_version_ 1792333392272949254
author Puri, A., Gulia, A.
author_facet Puri, A., Gulia, A., Puri, A., Gulia, A.
author_sort puri, a.
container_issue 9
container_start_page 1277
container_title The Journal of Bone and Joint Surgery. British volume
container_volume 94-B
description <jats:p>Rarely, the extent of a malignant bone tumour may necessitate resection of the complete humerus to achieve adequate oncological clearance. We present our experience with reconstruction in such cases using a total humeral endoprosthesis (THER) in 20 patients (12 male and eight female) with a mean age of 22 years (6 to 59). We assessed the complications, the oncological and functional outcomes and implant survival. Surgery was performed between June 2001 and October 2009. The diagnosis included osteosarcoma in nine, Ewing’s sarcoma in eight and chondrosarcoma in three. One patient was lost to follow-up. The mean follow-up was 41 months (10 to 120) for all patients and 56 months (25 to 120) in survivors. There were five local recurrences (26.3%) and 11 patients were alive at time of last follow-up, with overall survival for all patients being 52% (95% confidence interval (CI) 23.8 to 74) at five years. The mean Musculoskeletal Tumor Society score for the survivors was 22 (73%; 16 to 23). The implant survival was 95% (95% CI 69.5 to 99.3) at five years.</jats:p><jats:p>The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.</jats:p>
doi_str_mv 10.1302/0301-620x.94b9.29697
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTMwMi8wMzAxLTYyMHguOTRiOS4yOTY5Nw
imprint British Editorial Society of Bone & Joint Surgery, 2012
imprint_str_mv British Editorial Society of Bone & Joint Surgery, 2012
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229
issn 0301-620X, 2044-5377
issn_str_mv 0301-620X, 2044-5377
language English
last_indexed 2024-03-01T14:10:54.264Z
match_str puri2012theresultsoftotalhumeralreplacementfollowingexcisionforprimarybonetumour
mega_collection British Editorial Society of Bone & Joint Surgery (CrossRef)
physical 1277-1281
publishDate 2012
publishDateSort 2012
publisher British Editorial Society of Bone & Joint Surgery
record_format ai
recordtype ai
series The Journal of Bone and Joint Surgery. British volume
source_id 49
spelling Puri, A. Gulia, A. 0301-620X 2044-5377 British Editorial Society of Bone & Joint Surgery Orthopedics and Sports Medicine Surgery http://dx.doi.org/10.1302/0301-620x.94b9.29697 <jats:p>Rarely, the extent of a malignant bone tumour may necessitate resection of the complete humerus to achieve adequate oncological clearance. We present our experience with reconstruction in such cases using a total humeral endoprosthesis (THER) in 20 patients (12 male and eight female) with a mean age of 22 years (6 to 59). We assessed the complications, the oncological and functional outcomes and implant survival. Surgery was performed between June 2001 and October 2009. The diagnosis included osteosarcoma in nine, Ewing’s sarcoma in eight and chondrosarcoma in three. One patient was lost to follow-up. The mean follow-up was 41 months (10 to 120) for all patients and 56 months (25 to 120) in survivors. There were five local recurrences (26.3%) and 11 patients were alive at time of last follow-up, with overall survival for all patients being 52% (95% confidence interval (CI) 23.8 to 74) at five years. The mean Musculoskeletal Tumor Society score for the survivors was 22 (73%; 16 to 23). The implant survival was 95% (95% CI 69.5 to 99.3) at five years.</jats:p><jats:p>The use of a THER in the treatment of malignant tumours of bone is oncologically safe; it gives consistent and predictable results with low rates of complication.</jats:p> The results of total humeral replacement following excision for primary bone tumour The Journal of Bone and Joint Surgery. British volume
spellingShingle Puri, A., Gulia, A., The Journal of Bone and Joint Surgery. British volume, The results of total humeral replacement following excision for primary bone tumour, Orthopedics and Sports Medicine, Surgery
title The results of total humeral replacement following excision for primary bone tumour
title_full The results of total humeral replacement following excision for primary bone tumour
title_fullStr The results of total humeral replacement following excision for primary bone tumour
title_full_unstemmed The results of total humeral replacement following excision for primary bone tumour
title_short The results of total humeral replacement following excision for primary bone tumour
title_sort the results of total humeral replacement following excision for primary bone tumour
title_unstemmed The results of total humeral replacement following excision for primary bone tumour
topic Orthopedics and Sports Medicine, Surgery
url http://dx.doi.org/10.1302/0301-620x.94b9.29697